Understanding Pompe Disease: Current Trials and Integration Solutions

The diagnostic odyssey

Pompe Disease is a rare genetic disorder caused by the deficiency of the enzyme acid alpha-glucosidase, leading to the accumulation of glycogen in the body's cells. This accumulation can result in progressive muscle weakness and respiratory issues, significantly affecting the patients' quality of life. The challenge lies in the diagnostic odyssey that many patients face, characterized by a prolonged period of misdiagnosis or late diagnosis. Often, the symptoms of Pompe Disease can be mistaken for other neuromuscular disorders, complicating timely identification and intervention. As a result, eligible patients for clinical trials are difficult to locate, and many may go undiagnosed for years.

The trial landscape right now

Currently, there are three recruiting clinical trials focused on Pompe Disease, taking place across six countries with a total of 22 sites. The leading sponsors involved in these trials include Denali Therapeutics Inc., Duke University, and Shionogi. The geographical distribution of these trials highlights the engagement of the United States with eight sites, followed by the United Kingdom with five sites, and Germany, France, Spain, and Italy each hosting several sites.

Notable studies include:

• NCT01665326: "Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease" sponsored by Duke University in the United States.
• NCT07123155: "Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)" sponsored by Shionogi in the United Kingdom, currently in Phase II.
• NCT07354724: "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease" sponsored by Denali Therapeutics Inc. in the United States, currently in Phase I.

The ongoing trials reflect a concerted effort to advance the understanding and treatment of Pompe Disease, yet the difficulty in identifying eligible participants remains a significant barrier.

How we detect the match

A promising approach to enhancing patient recruitment for clinical trials involves integrating HL7 and FHIR standards with artificial intelligence (AI) capabilities. By leveraging existing clinical data structured according to FHIR resources such as Condition, Observation, MedicationRequest, and DiagnosticReport, healthcare systems can automate the identification of eligible patients.

The integration allows for the extraction of relevant lab results, genetic information, and ICD-10 codes that indicate the presence of Pompe Disease or its symptoms. For instance, computable phenotypes can be developed to identify patients with specific genetic markers or clinical presentations associated with the disease. This approach eliminates the need for exhaustive manual chart reviews, streamlining the process of matching patients to trials.

Beyond the trial: better care

The benefits of this data integration extend beyond clinical trial recruitment. By employing a systematic approach to patient identification, healthcare providers can shorten the diagnostic odyssey for individuals with Pompe Disease. Improved coordination of care can be achieved through enhanced monitoring and follow-up, ensuring that patients receive timely interventions regardless of their trial participation status. This integration fosters a holistic understanding of patient needs and facilitates a more proactive approach to managing Pompe Disease, ultimately leading to better health outcomes.

The takeaway

Pompe Disease presents significant challenges in diagnosis and treatment, but the current landscape of clinical trials and innovative data integration solutions offers hope for improved patient outcomes. By leveraging technology to identify eligible patients and streamline care, we can work towards overcoming the hurdles associated with this complex disorder.